Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses

International Immunopharmacology

Volumn 9, Issue 4, 2009, Pages 468-477

  Pun, Par Bahadur ^a   Bhat, Ajaz Ahmad ^a   Mohan, Teena ^a   Kulkarni, Smita ^b   Paranjape, Ramesh ^b   Rao, Donthamshetty Nageswara ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b NATIONAL AIDS RESEARCH INSTITUTE   (India)

Author keywords

CpG ODN; Microparticles; Secretory IgA

Indexed keywords

CPG 1826; CPG 2006; CPG OLIGODEOXYNUCLEOTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 C2 PEPTIDE ANTIGEN; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 FUSION DOMAIN PROTEIN; GLYCOPROTEIN GP 41 LEUCINE ZIPPER PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; NEF PROTEIN; NEUTRALIZING ANTIBODY; POLYGLYCOLIC ACID; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INDIA; INTESTINE LYMPHATIC TISSUE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS ENTRY; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; DNA; FEMALE; HIV ANTIGENS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES;

EID: 61649116885     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.01.012     Document Type: Article

References (44)

1. Yuki Y., Nochi T., and kiyono H. Progress towards an AIDS mucosal vaccine: an overview. C R Acad Sci III 322 (1999) 959-966
2. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 (2006) 148-158
3. Devito C., Broliden K., Kaul R., Svensson L., Johansen K., Kiama P., et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 1 (2000) 5170-5176
4. Manocha M., Pal P.C., Chitralekha K.T., Thomas B.E., Paranjape R., Kulkarni S., et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23 (2005) 5599-5617
5. Eldridge J.H., Meulbroek J.A., Staas J.K., Tice T.R., and Gilley R.M. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 251 (1989) 191-202
6. Chace J.H., Hooker N.A., Mildenstein K.L., Krieg A.M., and Cowdery J.S. Bacterial DNA - induced NK cell INF-γ production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopath 84 (1997) 185-193
7. Moldoveanu Z., Love-Homan L., Huang W.Q., and Krieg A.M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16 (1998) 1216-1224
8. Teleshova N., Kenney J., Williams V., Van Nest G., Marshall J., Lifson J.D., et al. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques. J Leukoc Biol 79 (2006) 257-267
9. Yamamoto S., Yamamoto T., and Tokunaga T. Oligodeoxyribonucleotides with 5'-ACGT-3' or 5'-TCGA-3' sequence induce production of interferons. Curr Topics Microbiol Immunol 247 (2000) 23-39
10. Santeliz J.V., Van Nest G., Traquina P., Larsen E., and Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyper responsiveness in a murine model of asthma. J Allergy Clin Immunol 109 (2002) 455-462
11. Hafner M., Zawatzky R., Hirtreiter C., Buurman W.A., Echtenacher B., Hehlgans T., et al. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res 61 (2001) 5523-5528
12. Merad M., Sugie T., Engleman E.G., and Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99 (2002) 1676-1682
13. Verthelyi D., Kenney R.T., Seder R.A., Gam A.A., Friedag B., and Klinman D.M. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 168 (2002) 1659-1663
14. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., Matsumoto M., Hoshino K., et al. A Toll-like receptor recognizes bacterial DNA. Nature 408 (2000) 740-745
15. Martin-Orozco E., Kobayashi H., Van Uden J., Nguyen M.D., Kornbluth R.S., and Raz E. Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol 11 (1999) 1111-1118
16. Chu R.S., Askew D., Noss E.H., Tobian A., Krieg A.M., and Harding C.V. CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. J Immunol 163 (1999) 1188-1194
17. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31 (2001) 3026-3037
18. Zarember K.A., and Godowski P.J. Tissue expression of human Toll-like Receptors and differential regulation of Toll-Like Receptor mRNAs in leukocytes in response to microbes, their products and cytokines. J Immunol 168 (2002) 554-561
19. Bauer M., Redecke V., Ellwart J.W., Scherer B., Kremer J.P., Wagner H., et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. J Immunol 166 (2001) 5000-5007
20. Krieg A.M. CpG motif in bacterial DNA and their immune effects. Ann Rev Immunol 20 (2002) 709-760
21. Wild C., Oas T., McDanal C., Bolognesi D., and Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci 89 (1992) 10537-10541
22. Sabatier J.M., Mabrouk K., Moulard M., Rochat H., Van Rietschoten J., and Fenouillet E. Anti HIV activity of muiltibranched peptide construct derived either from the cleavage sequence or from the transmembrane domain (gp41) of HIV-1 envelope. Virology 223 (1996) 406-408
23. Bosch M.L., Earl P.L., Forgnoii K., Piceifuocco S., Giombini F., Wongstaal F., et al. Identification of the fusion domain of primate immuno deficiency viruses. Science 244 (1989) 694-697
24. Chen Y.M., Lin R.H., Lee C.M., Fu C.Y., Chen S.C., and Syu W.J. Decreasing levels of anti-Nef antibody correlate with increasing HIV type 1 viral loads and AIDS disease progression. AIDS Res Hum Retroviruses 15 (1999) 43-50
25. Cheingsong-Popov R., Panagiotidi C., Ali M., Bowcock S., Watkins P., Aronstam A., et al. Antibodies to HIV-1 nef (p27): prevalence, significance, and relationship to seroconversion. AIDS Res Hum Retroviruses 6 (1990) 1099-1105
26. Lemasson I., Housset V., Calas B., and Devaux C. Antigenic analysis of HIV type 1 external envelope (Env) glycoprotein C2 region: implication for the structure of Env. AIDS Res Hum Retroviruses 11 (1995) 1177-1186
27. Sattentau Q.J., and Moore J.P. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 174 (1991) 407-415
28. Jeffery H., Davis S.S., and O'Hagan D.T. The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharm Res 10 (1993) 362-368
29. Barman S.P., Lunsford L., Chambers P., and Hedley M.L. Two methods for quantifying DNA extracted from poly (lactide-co-glycolide) microspheres. J Control Release 69 (2000) 337-344
30. Thakar M.R., Kumar B.K., Mhahjan B.A., Mehendale S.M., and Paranjape R.S. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV. Virology 359 (2007) 295-301
31. Heeney J., Akerblom L., Barnett S., Bogers W., Davis D., Fuller D., et al. HIV-1 vaccine-induced immune responses, which correlate with protection from SHIV infection: compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates. Immunol Lett 66 (1999) 189-195
32. Nelson J.A., Wiley C.A., Reynolds-Kohler C., Reese C.E., Margaretten W., and Levy J.A. Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet 1 (1988) 259-262
33. Kilian M., and Russel M.W. Function of mucosal immunoglobulins. In Handbook of Mucosal Immunology (1994), Academic Press p. 127
34. London S.D. Cytotoxic lymphocytes in mucosal effector sites. In Handbook of Mucosal Immunology (1994), Academic Press p. 263
35. Kiyono H., and Mc Ghee J.R. T helper cells for mucosal immune responses. In Handbook of Mucosal Immunology (1994), Academic Press p. 263
36. Mazanec M.B., Coudret C.L., and Fletcher D.R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 69 (1995) 1339-1343
37. Burns J.W., Siadat Pajouh M., Krishnaney A.A., and Breenberg H.B. Protective effect of rotavirus VP6-specific.IgA monoclonal antibodies that lack neutralizing activity. Science 272 (1996) 104-107
38. Brandtzaeg P., Farstad I.N., Johansen F.E., Morton H.C., Norderhaug I.N., and Yamanaka T. The B-cell system of human mucosae and exocrine glands. Immunol Rev 171 (1999) 45-87
39. Brandtzaeg P., Baklien K., Bjerke K., Rognum T.O., Scott H., and Values K. Nature and properties of the human gastrointestinal immune system. Immunology of the gastrointestinal tract (1987), CRC Press p. 1--85
40. Ahmad-Nejad P., Hacker H., Rutz M., Bauer S., Vabulas R.M., and Wagner H. Bacterial CpG-DNA and liposaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 32 (2002) 1958-1968
41. Phalipon A., Cardona A., Kraehenbuhl J.P., Edelman L., Sansonetti P.J., and Corthesy B. Secretory component: a new role in secretory IgA mediated immune exclusion In vivo. Immunity 17 (2002) 107-115
42. Brown L.E., White D.O., Agius C., Kemp B.E., Yatzakis N., Poumbourios P., et al. Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses. Arch Virol 140 (1995) 635-654
43. Pastori C., Barassi C., Piconi S., Longhi R., Villa M.L., Siccardi A.G., et al. HIV neutralizing IgA in exposed seronegative subjects recognize an epitope within the gp41 coiled-coil pocket. J Biol Regul Homeost Agents 14 (2000) 15-21
44. White J.M. Viral and cellular membrane fusion proteins. Annu Rev Physiol 52 (1990) 675-697